IPH.PA

Innate Pharma

IPH.PA, France

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

https://www.innate-pharma.com

Stock Price

€0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IPH.PA
stock
IPH.PA

Apple Stock Lags ‘Mag 7’ Peers: Analyst Sees ‘Solid’ iPhone Revenue Amid Risk Of Higher Memory Costs Stocktwits

Read more →
IPH.PA
stock
IPH.PA

Analysts Are Hot on the Foldable iPhone. Should You Buy AAPL Stock Before Apple’s Next Big Product Launch? Barchart.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

BUY

$

Analyst Picks

Strong Buy

0

Buy

2

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

25.86

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-414.93 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-22.97 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-642.43 %

Low 5%

High 15%

Debt to Equity

-

Very Low

17.07

Low 1

High 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Innate Pharma

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.12

Latest Release

Date

2025-09-30

EPS Actual

-0.12

EPS Estimate

0

EPS Difference

-0.12

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Weak Deep Value(3)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-06-30)

Revenue

€ 0

Cost Of Revenue

€ 0

Gross Profit

€ 0

Operating Expenses

€ 0

Operating Income

€ 0

Interest Expense

€ 0

Pretax Income

€ 0

Net Income

€ 0

Income Tax Expense

€ 0

EBITDA

€ 0

Total Other Income Expense Net

€ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

0

Short Term Investments

0

Receivables

0

Inventories

0

Total Current Assets

0

Property Plant Equipment

0

Total Assets

0

Payables

0

Short Term Debt

0

Long Term Debt

0

Total Liabilities

0

Equity

0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

0

Depreciation

0

Change In Working Capital

0

Cash From Operations

0

Capital Expenditures

0

Cash From Investing

0

Cash From Financing

0

Net Change In Cash

0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.